Litigation Details for UCB, Inc. v. Annora Pharma Private Limited (D. Del. 2020)
✉ Email this page to a colleague
UCB, Inc. v. Annora Pharma Private Limited (D. Del. 2020)
| Docket | ⤷ Sign Up | Date Filed | 2020-07-24 |
| Court | District Court, D. Delaware | Date Terminated | 2023-09-12 |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | None | Referred To | Jennifer L. Hall |
| Patents | 6,784,197; 6,911,461; 8,492,416 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in UCB, Inc. v. Annora Pharma Private Limited
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for UCB, Inc. v. Annora Pharma Private Limited (D. Del. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2021-09-10 | 118 | Notice of Service | Amended Invalidity Contentions regarding U.S. Patent No. 6,911,461 filed by Annora Pharma Private Limited, … 12 September 2023 1:20-cv-00987 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2021-10-12 | 128 | Notice to Take Deposition | Invalidity Contentions Regarding U.S. Patent No. 6,911,461. 4. The term “Your ANDA…assessment, analysis, or opinion regarding the ’461 Patent, including the validity and enforceability thereof…18. Your knowledge of prior art to the ’461 Patent including Your knowledge of the references cited…Your Notice Letter to UCB regarding the ’461 Patent, including but not limited to the entire “detailed…ANDA Product prior to expiration of the ’461 Patent and the final resolution of this litigation, including | External link to document |
| 2022-01-11 | 188 | Letter | analyses of the validity of U.S. Patent No. 6,911,461 (“the ’461 Patent”). UCB respectfully requests that…validity of the ’461 Patent—the only issue raised with respect to the only patent at issue in this lawsuit—are…stipulated to infringement of all claims of the ’461 Patent, which covers Briviact and its active ingredient… scope, validity, or enforceability of the ’461 Patent.” Ex. B at 11. After an agreed-upon extension …in this litigation is the validity of the ’461 Patent. See D.I. 57 at 28–29. There can be no reasonable | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
